Načítá se...
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy
Background. Natalizumab is a highly effective treatment approved for multiple sclerosis (MS). The opening of the blood-brain barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis. Our goal was to verify the utility of serum levels of active MMP-2 and MM...
Uloženo v:
| Vydáno v: | Dis Markers |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi Publishing Corporation
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4909921/ https://ncbi.nlm.nih.gov/pubmed/27340316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/8434209 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|